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Abstract 





Novel psychoactive substances (NPS) are defined as substances, either in pure form or in preparation, 
that have not been scheduled under the 1961 United Nations Single Convention on Narcotic Drugs or the 
1971 United Nations Convention on Psychotropic Substances, but which may pose a public health threat 
comparable to the substances there listed [1]. The use of NPS, peculiarly by adolescents and young adults, 
is emerging as a new trend worldwide [2], shaping an unprecedented and dangerous global phenomenon 
in the field of substance misuse. The short- and long- term health risks associated with the consumption 
of novel psychoactive substances are, in fact, often unknown to both users and health professionals [3].  
Among NPS, synthetic cannabinoids (SC) are the largest and most prevalent group [4]. SC are chemically 
heterogeneous and structurally dissimilar from delta-9-tetrahydrocannabinol (THC), but they all share a 
  
common mechanism of action, being agonists of the endocannabinoid system receptors CB1 and CB2 
[5]. SC are usually sold as “legal” alternatives to natural cannabis, and they gained popularity in the early 
2000s with the appearance on the market of the Spice brand [6], which is the reason they are still often 
referred to as Spice drugs. As many other NPS, most SC are neither recently patented, nor originally 
synthesised as recreational drugs: one of the widest series of SC was developed in the 1990s by John 
William Huffman [7], who was an organic chemistry professor at Clemson University researching on 
cannabinoid compounds as possible therapeutic options for multiple sclerosis and HIV. SC are easy to 
be purchased, not only from smart shops, but also online: the number of web pages offering SC for sale 
to European customers has been constantly growing since 2010 [8]. Potential consumers may be attracted 
by marketing strategies such as cheap prices, colourful and apparently “harmless” names and packaging, 
and the often false believe to be buying something legal, and therefore safe [9, 10]. SC are produced in 
clandestine laboratories, located mostly in India and China, either as pure powder, sold as a research 
chemical, or vaporised and sprayed on dried plants material, advertised as “herbal incenses” [11]. All 
products containing SC are labelled “not for human consumption”; nevertheless, SC are primarily 
smoked or inhaled by users to obtain a quick “high”. SC prevalence presents significant differences be-
tween Europe and US: according to the most recent American data, the use of SC may be declining 
among young adults (5.8% in 2014, in comparison with 7.9% in 2013 and 11.3% in 2012), while Euro-
pean surveys highlight increasing trends [12]. A growing interest in the field is also registered by scien-
tific literature: a PubMed and Scopus search performed on November 8th, 2016 for the following terms 
“synthetic cannabinoid*”, “synthetic cannabimimetic*”, “synthetic cannabis”, “synthetic marijuana” and 
“Spice AND cannabinoid*” yielded a total of 162 relevant results, mainly published in the past two years 
(exclusion criteria: papers not in English; mini reviews, letters, book chapters, case reports erratum; pa-
pers related to SC as therapeutic options). Most results (93) emerged for the keyword “synthetic canna-
binoid*”, followed by the combination “Spice* AND “cannabinoid*” (42), accounting respectively for 
57% and 26% of the total. Only about 9% of the results were case report or case series: most papers were 
epidemiological, forensic, toxicologic, or analytical. 3% of the studies were on animal models. 
Aim of the present paper is to provide a synthesis of the most recent and relevant insights on the phar-







Whilst THC, the main active component of natural cannabis, is a partial agonist at cannabinoid receptors 
CB1 and CB2, SC can be full, or even super agonists [13, 14], hence possessing high levels of receptors’ 
affinity whilst eliciting maximal activity on cannabinoid receptors [5]. CB1 and CB2 agonism of SC is 
also potentiated by a slow rate of dissociation from cannabinoid receptors [15]. The effects of SC are 
also achieved through reversible indirect dopamine stimulation [16-17] and activation of G-protein-cou-
pled receptors [18].  Consecutive stimulation of the neurotransmitters is associated with enhanced meta-
bolic activity throughout the brain, especially in rewarding and reinforcing centres, i.e. nucleus accum-
bens, amygdala, cingulate cortex, prefrontal cortex, ventral pallidum, caudate putamen, ventral tegmental 
area, and lateral hypothalamus [19-20]. Additionally, exogenous CB1 activation with SC reveals sen-
sorimotor and motor alteration accompanied by significant modifications of the activity in visual and 
auditory cortices [21-22]. Each “new generation” within the class of SC demonstrates greater potency on 
CB receptors compared to earlier ones [23-24-25-26]. In contrast, THC and “old generation” SC show a 
more significant inhibitor ability on hippocampal and cerebellum glutamate transmission [27-28]. The 
  
potency and duration of the pharmacological effects may be partially explained by the retention of CB1 
agonism in the process of their metabolism.  For instance, hydroxylated compounds demonstrate equal 
or greater efficacy with respect to THC [29-30]. Additionally, SC metabolites reveal CB2 receptors af-
finity, distributing immune reactions and modulating addictive properties [31]. The grade of SC toxicity 
can be also determined and associated with polymorphic alleles of the metabolising enzyme P450 [32]. 
The pharmacological properties of SC go beyond neurotransmission, and include cytotoxicity and ge-
netic effects. SC can cause cell damaging through affecting lipid metabolism and inflammatory signalling 
[33]. Chronic systemic exposure can modify the structure of cortical and sub-cortical neurons [34], with 
effects on nuclei and nucleus membranes [35] and suppression of neuronal activity in the hippocampus 
[36-37]. Metabolites of SC also demonstrate neurotoxic effects decreasing cellular viability, apoptosis 
and necrosis [38-39] as well as DNA damaging and micronuclei aberration of chromosomes [40-41]. The 
genotoxicity of SC also refers to hepatocytes, lymphocytes and cells of cardiovascular system. In these 
cases, acute and chronic exposure to SC may induce genes significantly associated with dysfunction of 
oxidation and inflammation in liver, cardio-vascular and blood systems [42-43].  Taking into considera-
tion the endocannabinoid regulation properties on reproductive system, SC showed a damaging effect on 
gonads.  In series of experiments with human cell lines and primary cells, SC represented hormonal 
antiestrogenic activity [44]. In turn, long-term use of SC can have adverse effects on both spermatogen-
esis and sperm function acting on spermal endocannabinoid system [45].   
Chronic exposure to SC associates with abuse liability, and determines behavioural activity in form of 
modulation of discriminative stimulus effects [46-47]. Furthermore, repeated SC administration can lead 
to modulation, internalisation and desensitisation of CB receptors, linked to tolerance and withdrawal 
symptoms [48-49]. 
Furthermore, THC effects are mitigated by the presence of other compounds identified in cannabis, e.g. 
terpenoids, cannabidiol and tetrahydocannabivarin [50], while none of these ‘modulating’ compounds 
are detected in SC, a number of SC molecules incorporates indole-derived moieties as components of the 
structure or as substituents [51], typically identified in indoleamine hallucinogens such as dimethyltryp-
tamine [52]. Moving from this point of view, it could be argued that the intake of indole SC compounds 
may be associated with significant levels of 5-HT receptors’ activation [53,54]. SC demonstrates also 
interactions with other transmission systems, namely µ-opioid [55], glutamate and GABA [56]. Mean-
while, for some SC agents abuse potential contributes also to alteration in neurobiological function, cog-
nitive potency or behaviour without significant influence on rewarding or reinforcing systems [57-58]. 
Overall, SC activity at non-cannabinoid receptors may well contribute to the complex clinical effects 
observed [5].   
As SC-containing preparations are almost always produced mixing multiple SC in a single product [59], 
there is a strong potential for between–drug interactions [60]. Furthermore, some SC metabolites retain 
levels of both affinity and activity for CB1 receptors, hence delaying/intensifying receptors’ activation 
and contributing to the toxicity of the products [61]. The recent trend of SC fluorination, commonly 
applied in medicinal chemistry, may increase the compounds’ lipophilicity, promoting the absorption 
through biological membranes/blood brain barrier [62, 63], possibly enhancing CB receptor affinity [64] 
the overall toxicity [61]. Other factors potentially contributing to SC toxic effects may include: the phar-
macological activity of SC pyrolysis by-products [65, 66]; the presence of contaminants, side-products, 
and solvents in the package [59]; the lack of any quality control of the final product, leading to significant 
differences in concentration (‘hot-spots’) of SC present in herbal incenses [50, 67]; and the increased 
vulnerability to some SC adverse effects due to either pre-existing conditions of drug users, or concurrent 






Desired effects arise quickly after the consumption of SC products, and include euphoria, talkativeness, 
feelings of joy and laughter, relaxation [69]. In terms of psychoactive effects, there are similarities be-
tween low doses of SC and THC intake [70], as delusional and hallucinatory symptoms most commonly 
occur for higher SC doses. Nevertheless, it has to be considered that determining the exact dosage of a 
single SC in a preparations is usually extremely difficult, if not impossible, for the user [10]. SC-related 
perceptual disturbances may include ‘fractals/ geometric patterns’, ‘trails’, and ‘flashes of colour’, to-
gether with relaxation and increased creativity levels [71]. With respect to cannabis, SC intake may also 
be associated with quicker arise of the effects, shorter duration of action, and larger levels of hangover 
[72]. High SC dosages may induce increasing levels of anxiety [73], together with a range of unpleasant 
experiences (e.g. ‘bad trips’). Bad trips are characterised by a range of symptoms such as: suspicious-
ness/paranoid feelings, altered experience of one’s self, and sensations of living in different/parallel re-
alities [74-76].   SC	  psychoactive	  effects	  may	  be	  more	  intense	  in	  individuals	  with	  any/minimal	  levels	  of	  previous	  exposure	  to	  cannabis	  [77].	  Adverse	  SC-­‐‑related	  side	  effects	  may	  be	  severe;	  indeed,	  SC	  intake	  is	  as-­‐‑sociated	  with	  a	  30-­‐‑fold	  higher	  risk	  of	  seeking	  emergency	  room	  as	  compared	  with	  traditional	  can-­‐‑nabis	  [78].	  	  The	  risk	  of	  two	  widespread	  symptoms	  of	  SC	  intoxication,	  namely	  agitation	  and	  cardio-­‐‑toxicity,	  exceeds	  this	  of	  traditional	  cannabis	  of	  3.8	  and	  9.2	  times	  respectively	  [79].	  Acute	  SC	  intox-­‐‑ication	  may	  sometimes	  resemble	  the	  clinical	  picture	  associated	  with	  the	  use	  of	  stimulant/sympa-­‐‑thomimetic	   recreational	   drugs	   [80,82,83].	  On	   other	   occasions,	   a	   short-­‐‑standing,	   potentially	   life	  threatening,	  serotonin-­‐‑like	  syndrome	  may	  be	  observed,	  with	  reported	  signs/symptoms	  of	  elevated	  heart	  rate/blood	  pressure	  levels;	  mydriasis;	  agitation/anxiety;	  hyperglycaemia;	  dyspnoea/tach-­‐‑ypnoea;	   nausea/vomiting;	   diaphoresis,	   hot	   flushes	   and	   seizures,	   hyperthermia	   [5,	   77,	   82-­‐‑84].	  Other	  SC-­‐‑related	  acute	  adverse	  effects	  include:	  somnolence,	  self-­‐‑injurious/aggressive	  behaviour;	  hyperemesis;	  nystagmus;	  stroke;	  chest	  pain,	  myocardial	  infarction;	  rhabdomyolysis,	  risk	  of	  cardi-­‐‑ovascular	  diseases	  including	  alteration	  in	  ECG	  parameters,	  limb	  twisting,	  muscle	  tremors,	  respir-­‐‑atory	  failure,	  catatonia,	  losses	  of	  consciousness	  and	  acute	  kidneys	  injuries,	  ,	  elevation	  of	  creatine	  kinase,	  cerebral	  ischaemia,	  metabolic	  derangements	  (hypokaliemia,	  insulin	  resistance,	  metabolic	  acydosis)	   [85-­‐‑99].	  Metabolic	  decompensation	   initiated	  by	  SC	  may	  contribute	   to	  and	  exaggerate	  neurotoxic	  effects	  that	  anecdotal	  report	  on	  adrenoleukodystrophy	  suggests	  [100].	  Neurotoxic	  ef-­‐‑fects	  of	  SC	  are	  clinically	  confirmed	  by	  morphometric	  assays	  in	  form	  of	  reduction	  of	  thalamus	  and	  cerebellum,	  grey	  matter	  and	  white	  matter	  of	  left	  temporal	  lobe,	  subcortical	  structures	  and	  brain-­‐‑stream	  	  [101-­‐‑102].	  Conditions	  of	  agitated/excited	  delirium	  have	  recently	  been	  associated	  with	  SC	  intoxication	   [103-­‐‑106].	   Patients	  may	   be	   very	   aggressive,	   hallucinating,	   combative,	   suicidal	   and	  tachycardic	  for	  up	  to	  several	  days	  [71,	  107-­‐‑108].	  Overall,	  so	  far	  most	  clinicians	  are	  not	  well	  trained	  in	  terms	  of	  treatment/management	  issues	  relating	  to	  SC	  misuse	  and	  intoxication	  [109].	  A	  number	  of	  deaths	  have	  been	  related	  to	  SC	  ingestion,	  either	  on	  their	  own	  or	  in	  combination	  with	  other	  rec-­‐‑reational	  drugs/prescription	  drugs	  [110-­‐‑115].	  Conversely,	  there	  are	  no	  reports	  of	  fatal	  cannabis	  overdoses	  in	  the	  epidemiological	  literature	  [116].	  
Both tolerance and symptoms of withdrawal have been described for SC, suggesting that they may have 
a relatively high abuse and dependence liability [71, 117-118]. SC withdrawal syndrome is characterised 
by drug craving, tachycardia, tremor, profuse sweating, nightmares/insomnia, headache, anxiety/irrita-
bility, and feelings of emptiness/depressive symptoms, cenestopathic sensations and somatic complaints 
  
(chest pain, dyspnoea, nausea /vomiting, diarrhoea, diaphoresis, palpitation [119-122] Severe symptoms 





Synthetic Cannabinoids and Psychosis  
 
SC are more psychoactive than cannabis, helping to achieve the desire of feeling “high”, easily available 
as “legal” product, and undetectable in routine examinations: these factors may increase their popularity 
among different populations, such as high school seniors [124], young people and adolescents [125], 
with men being more consumers than women [126].  SC do not contain any cannabidiol (or other mod-
ulating compounds) that may counteract the psychoactive properties, and their intrinsic activity on CB1 
receptors, spread over CNS, is maximal [5, 66]. Psychotic disorders associated with SC intake can be 
conceptualised as: toxic acute psychotic episodes [77, 127-132]; ‘ex novo’, long-standing/persistent, psy-
chotic disorders [68,133-134]; and relapse/worsening of a pre-existing psychosis [77, 135-137]. The ex-
act mechanism of association is not well understood and still debated. Family history, childhood trauma, 
age of exposure and genetics are thought to be the mediators and moderators of the association between 
SC and psychosis effects [138,139]. Acute psychotic reactions in healthy individuals can occur following 
either a single or repeated use of SC, and may include a wide range of clinically relevant positive, nega-
tive and cognitive psychopathological symptoms that mimic symptoms of schizophrenia, among which: 
perceptual alterations, depersonalisation, dissociation, illusions, auditory and visual hallucinations, par-
anoid delusions, bizarre/disorganised behaviour and speech, catatonia, agitation/aggression, and suicidal 
ideation/behaviour. Negative symptoms including blunted affect, emotional withdrawal, psychomotor 
retardation, lack of spontaneity, and reduced rapport are less frequently seen in studied SC users than in 
schizophrenic patients [140]. SC may exacerbate symptoms in patients already diagnosed with psychotic 
illness [138-140]. Acute psychosis outlasting the period of intoxication, and persistent disorders are still 
under study.  So far, no longitudinal studies to evaluate the impact of long-term effects of SC consump-
tion have been carried out in humans. However, a cross sectional study on 81 male patients diagnosed 
with psychotic disorders induced by at least 4 months of SC use was performed to identify the clinical 
psychotic characteristics induced by SC in relation to schizophrenia [141]. Results revealed that SC-
induced psychosis shows remarkable states of suicidal ideation, as well as schizomimetic psychotic fea-
tures. Younger age at onset is related to poor frontal lobe functioning domains, specifically affected by 
SC [141]. Occurrence of hallucinations/delusions is less likely with cannabis than with SC; the phenom-
enon has been observed in 2% and 11.2% of misusers, respectively [125]. Furthermore, in comparison 
to cannabis, SC-related psychotic episodes are associated with more frequent and higher levels of agita-
tion/behavioural dyscontrol [142]. Overall, comparative studies of SC vs cannabis users admitted to psy-
chiatric units show that SC users are generally younger, and presenting with: higher rates of compulsory 
admissions; higher severity of disease; more frequent levels of aggression; and longer length of admis-
sion [143, 144].  Finally, a number of complete suicides following SC intake has been described 
[110,145-147]. No extensive literature available on this topic and further studies needed to reveal the 










Table	  1:	  	  Case	  histories,	  pathology	  and	  toxicology	  findings,	  and	  	  death	  cause	  for	  15	  SC-­‐‑related	  fatali-­‐‑
ties	  	  
	   Ref.	  	   Age	  /sex	   Witnessed	  symptoms	   Pathology	  on	  autopsy	   Hx	  of	  signif-­‐‑icant	  dis-­‐‑ease	   SC	  de-­‐‑tected	   History	  of	  drug	  abuse	   Medical	  examiner	  certificate	  149	   29	  	  	  F	   Signs	  of	  intoxica-­‐‑tion	  &	  agi-­‐‑tation	  	  
unremarkable	   N/A	   XLR-­‐‑11	   Herbal	  incense/	  potpourri.	  Black	  Dragon	  packages	  
Accident	  death	  with	  SC	  toxicity	  
149	   32	  	  F	   Chest	  pain,	  nausea,	  agitation	  	   Pulmonary	  oedema/	  an-­‐‑thracosis,	  acute	  visceral	  congestion	  	  
 XLR-­‐‑11	   Methampheta-­‐‑mine,	  Heroin,	  	  SC	   Accident	  death	  with	  SC	  intoxi-­‐‑cation	  	  
  
150	   41	  F	   Violent,	  aggressive	  with	  her	  family	  
pulmonary	  oedema,	  vas-­‐‑cular	  conges-­‐‑tion,	  occlu-­‐‑sion	  of	  LAD	  coronary	  ar-­‐‑tery	  with	  is-­‐‑chemia	  of	  the	  anterior	  left	  ventricular	  	  
N/A	   ADB-­‐‑FU-­‐‑BINACA	   SC	  “Mojo”	   Coronary	  artery	  oc-­‐‑clusion	  	  with	  SC	  in-­‐‑toxication	  
151	   34	  M	   Rigor	  mor-­‐‑tis,	  nasal	  frothy	  purge	  sub-­‐‑stance	  
N/A	   unremarka-­‐‑ble	   5F-­‐‑AMB	   Ethanol	  abuse	  SC	  “Apollo	  bag	  was	  found	  in	  his	  pocket”	  
Accident	  death	  with	  SC	  toxicity	  
110	   57	  M	   Unrespon-­‐‑sive	  	   Enlarged	  heart	   N/A	   JWH-­‐‑018	   Herbal	  incense,	  spice,	  white	  powdery	  sub-­‐‑stance.	  Prescrip-­‐‑tion	  drugs	  held	  with	  him.	  
N/A	  
110	   52	  M	   Nude	  and	  unrespon-­‐‑sive	  	   N/A	   N/A	   JWH-­‐‑018	  JWH-­‐‑073	   Herbal	  incense.	  “K2”	  package	  was	  found	   N/A	  110	   29	  M	   Commit-­‐‑ted	  suicide	   N/A	    JWH-­‐‑018	  JWH-­‐‑073	   “K2”	  herbal	  blend	  	   N/A	  152	   17	  M	   Gasped	  the	  air	  and	  fell	  down.	  	   unremarkable	    5F-­‐‑PB-­‐‑22	   Alcohol	  &	  SC	   Accident	  death	  with	  SC	  toxicity	  
152	   27	  M	   Ill	  &	  dia-­‐‑phoretic	   fulminant	  liver	  failure	   N/A	   THCCOOH	  5F-­‐‑PB-­‐‑22	   Marijuana	  	   Accident	  death	  with	  SC	  toxicity	  
  
152	   18	  M	   Unrespon-­‐‑sive	  &	  cool	  to	  touch	   	  bilateral	  pul-­‐‑monary	  and	  abdominal	  or-­‐‑gans	  conges-­‐‑tion	  	  
N/A	   5F-­‐‑PB-­‐‑22	   K2	  &	  spice	   Accident	  death	  with	  SC	  toxicity	  
152	   	  	  19	  M	  
	  	  Uncon-­‐‑scious	  with	  drinking	  	  
	  	  bilateral	  pul-­‐‑monary	  oe-­‐‑dema,	  ne-­‐‑crotizing	  granuloma-­‐‑tous	  inflam-­‐‑mation	  with	  histoplasma	  microorgan-­‐‑isms	  and	  con-­‐‑gestion	  of	  vis-­‐‑cera.	  
	  	  N/A	   	  	  5F-­‐‑PB-­‐‑22	   	  	  N/A	   	  	  Accident	  death	  with	  SC	  toxicity	  
153	   	  34	  M	   	  Dead	  in	  bedroom	  	   	  Asphyxia	  due	  to	  aspiration	  of	  gastric	  con-­‐‑tents	  
 	  5F-­‐‑AMB	  AB-­‐‑CHMINACA	  
	  Herbal	  blend	  	  	  3	  herbal	  pack-­‐‑ages	  were	  found	  with	  him	  
	  Accident	  death	  with	  SC	  toxicity	  
154	   25	  M	   Found	  dead	  in	  his	  kitchen	   Brain	  &	  pul-­‐‑monary	  oe-­‐‑dema	  with	  subepicardial	  petechial	  haemorrhage	  
Insulin	  de-­‐‑pendent	  di-­‐‑abetes	  mellitus	  	  
AB-­‐‑CHMINACA,	  AB-­‐‑FU-­‐‑BINACA,	  5F-­‐‑APINACA,	  5F-­‐‑AMB,	  STS-­‐‑135,	  THJ2201,	  AM2201,	  EAM-­‐‑2201,	  JWH-­‐‑122	  and	  MAM2201	  
SC	  	  	  	  self-­‐‑made	  bong	  &	  cannabis	  mill	  were	  found	  in	  his	  room”	  
Diabetic	  ketoacido-­‐‑sis	  wih	  SC	  intoxica-­‐‑tion	  	  
  
154	   25	  M	   Un	  re-­‐‑sponsive.	  All	  re-­‐‑flexes	  lost	  
Multiple	  or-­‐‑gan	  failure	    MDMB-­‐‑CHMICA	   SC	  “Mocarz,	  combing	  comb	  ,	  Baka”	  ethanol	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